Oncolin Therapeutics Announces Its Lead Technology Has Shown to Be Effective in Treating Cancer in Animal Models
HOUSTON--(BUSINESS WIRE)--April 14 -- Oncolin Therapeutics,
Inc., (OTCBB:OCOL - News) (Oncolin) announces that one of its lead
drug candidates has shown in preclinical testing that it extends
the life of animals that have human tumors implanted in their
brains. The early testing has yielded results in animals that are
equivalent to that of Temodar®, which is one of the leading
cancer treatments for brain cancer with annual revenues in excess
of $500 million annually. This technology is covered under
Oncolin’s recent exclusive option to license from The
University of Texas M.D. Anderson.
In further studies it was determined that the administration of a
combination of our compound with Temodar® produces superior
anti-tumor activity when compared to Temodar® alone, resulting
in increased survival.
“Even though these tests are very early stage they have generated some very positive results which validate our theory of this treatment. We are continuing to undertake and complete the preclinical studies required for a goal of beginning a phase I trial by the beginning of 2009,” said Dr. Donald Picker, President and COO.
Recent News
Oncolin Therapeutics Obtains an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment
Oncolin has recently announced that is has obtained an exclusive option agreement with the Pharmaceutical Research Institute of Warsaw, Poland, which provides the company the right to license the use of Genistein analogs for cancer treatment.
Oncolin Announces Its Research Program Receives Peer Reviewed National Institute of Health Grant of $179,000.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.
Safe Harbor Statement
This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin's future business and financial results, refer to Oncolin's Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.
Contact:
Oncolin Therapeutics, Inc., Houston
J. Leonard Ivins, 713-621-5208
Investors@oncolinthera.com
Posted: April 2008
